Narendra Modi holds review meeting on COVID-19 vaccination strategy; regulatory approvals, procurement discussed
Additionally, Modi said, issues like prioritisation of population groups and tech platform for rolling out vaccine for the coronavirus were also brought up
New Delhi: Prime Minister Narendra Modi on Friday held a meeting to review India's vaccination strategy, in which issues like prioritisation of population groups and tech platform for rolling out vaccine for the coronavirus were discussed.
Held a meeting to review India’s vaccination strategy and the way forward. Important issues related to progress of vaccine development, regulatory approvals and procurement were discussed. pic.twitter.com/nwZuoMFA0N
— Narendra Modi (@narendramodi) November 20, 2020
Modi tweeted that the meeting discussed important issues related to the progress of vaccine development, regulatory approvals and procurement.
"Reviewed various issues like prioritisation of population groups, reaching out to HCWs (health care workers), cold-chain Infrastructure augmentation, adding vaccinators and tech platform for vaccine roll-out," he said.
A number of COVID-19 vaccine candidates are in advanced phases of trial.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
WHO advises against use of Remdesivir to treat COVID-19, says drug has no 'important effect' to reduce deaths
A WHO Guideline Development Group of international experts said there was 'no evidence based on currently available data that the anti-viral drug does improve patient-important outcomes'
WHO hails COVID-19 vaccine news after Moderna's progress, but warns there's 'no time for complacency'
WHO chief Tedros Adhanom Ghebreyesus warned that widespread availability of any vaccine remains a long way off, amid rising COVID-19 cases and deaths across the world
Italy's special commissioner for the virus emergency said he expected Pfizer's authorization from the European Medical Agency to be completed in time for the first vaccines to be administered in January